Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2014 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
APTINYX INC | 20 | Q1 2023 | 16.9% |
SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
SAVARA INC | 19 | Q2 2024 | 6.4% |
X4 PHARMACEUTICALS INC | 19 | Q2 2024 | 3.2% |
ARCUTIS BIOTHERAPEUTICS, INC. | 18 | Q2 2024 | 20.1% |
SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
MERSANA THERAPEUTICS, INC. | 17 | Q2 2024 | 8.4% |
DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
ANNEXON INC | 16 | Q2 2024 | 9.1% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-12 |
13F-HR | 2024-05-15 |
4 | 2024-02-14 |
13F-HR | 2024-02-13 |
3 | 2024-02-07 |
4 | 2024-01-12 |
3 | 2023-12-29 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.